Journal
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
Volume 8, Issue 2, Pages 116-122Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-013-0154-5
Keywords
Acute myeloid leukemia; Myeloproliferative neoplasm; Myeloproliferative disorder; Blast phase; Cytogenetics; Genetics; Hypomethylating; JAK inhibitor; Clonal; Classification; Response
Categories
Funding
- Medicom Worldwide
Ask authors/readers for more resources
Acute myeloid leukemia (AML) is an uncommon, but often deadly complication of myeloproliferative neoplasms (MPN). Post-MPN AML usually occurs years after the initial MPN diagnosis with an average age of onset between 64 and 68 years. Chromosome abnormalities are common and many patients have cytogenetic changes that are associated with poor risk features. Post-MPN AML is characterized by acquired somatic gene mutations, but, interestingly, mutations thought to have an etiologic role in the MPN, such as JAK2V617F, are sometimes absent in the AML clone. Conventional AML-style treatment appears to have limited efficacy, although when coupled to allogeneic stem cell transplantation, some patients have long-term survival. Less-intensive therapies such as hypomethylating agents and the JAK inhibitor, ruxolitinib, may be effective in some patients. New treatments have prompted efforts to characterize therapeutic responses better.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available